ALK and non-small cell lung carcinoma: Anaplastic lymphoma receptor tyrosine kinase (ALK) translocations are used for identifying patients with NSCLC likely to benefit from crizotinib.19, 20 However, existing biomarkers are not sensitive enough to provide real‐time information on the effectiveness of chemotherapy.